Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor.

Pilot-Storck F, Chopin E, Rual JF, Baudot A, Dobrokhotov P, Robinson-Rechavi M, Brun C, Cusick ME, Hill DE, Schaeffer L, Vidal M, Goillot E.

Mol Cell Proteomics. 2010 Jul;9(7):1578-93. doi: 10.1074/mcp.M900568-MCP200. Epub 2010 Apr 5.

2.

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.

Carraway H, Hidalgo M.

Breast Cancer Res. 2004;6(5):219-24. Epub 2004 Aug 12. Review.

3.

Recent advances in the protein kinase B signaling pathway.

Woodgett JR.

Curr Opin Cell Biol. 2005 Apr;17(2):150-7. Review.

PMID:
15780591
4.

Review of the complexities of the PI3K/mTOR pathway presages similar handling of other critical topics.

Alfred Yung WK.

Neuro Oncol. 2010 Aug;12(8):763-4. doi: 10.1093/neuonc/noq083. Review. No abstract available.

5.

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Liang J, Slingerland JM.

Cell Cycle. 2003 Jul-Aug;2(4):339-45. Review.

PMID:
12851486
6.

Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase.

Gold MR, Ingham RJ, McLeod SJ, Christian SL, Scheid MP, Duronio V, Santos L, Matsuuchi L.

Immunol Rev. 2000 Aug;176:47-68. Review.

PMID:
11043767
7.

mTOR signaling in glioblastoma: lessons learned from bench to bedside.

Akhavan D, Cloughesy TF, Mischel PS.

Neuro Oncol. 2010 Aug;12(8):882-9. doi: 10.1093/neuonc/noq052. Epub 2010 May 14. Review.

8.

Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.

Wang H, Brown J, Martin M.

Cytokine. 2011 Feb;53(2):130-40. doi: 10.1016/j.cyto.2010.10.009. Epub 2010 Nov 23. Review.

9.

Human β-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map.

Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocaña A.

Diabetes. 2014 Mar;63(3):819-31. doi: 10.2337/db13-1146. Review.

10.

mTOR signaling in lymphangioleiomyomatosis.

Kristof AS.

Lymphat Res Biol. 2010 Mar;8(1):33-42. doi: 10.1089/lrb.2009.0019. Review.

11.

Glycogen synthase kinase 3 substrates in mood disorders and schizophrenia.

Cole AR.

FEBS J. 2013 Nov;280(21):5213-27. doi: 10.1111/febs.12407. Epub 2013 Jul 15. Review.

12.

Central nervous system nutrient signaling: the regulation of energy balance and the future of dietary therapies.

Stefater MA, Seeley RJ.

Annu Rev Nutr. 2010 Aug 21;30:219-35. doi: 10.1146/annurev.nutr.012809.104723. Review.

PMID:
20225935
13.

Is glycogen synthase kinase-3 a central modulator in mood regulation?

Li X, Jope RS.

Neuropsychopharmacology. 2010 Oct;35(11):2143-54. doi: 10.1038/npp.2010.105. Epub 2010 Jul 28. Review.

14.

Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Beurel E, Michalek SM, Jope RS.

Trends Immunol. 2010 Jan;31(1):24-31. doi: 10.1016/j.it.2009.09.007. Epub 2009 Oct 14. Review.

15.

A year in structural signaling: mTOR--the PIKK of the bunch?

Smerdon SJ.

Sci Signal. 2014 Mar 4;7(315):pe6. doi: 10.1126/scisignal.2005174. Review.

PMID:
24595107
16.

Mammalian two-hybrids come of age.

Lievens S, Lemmens I, Tavernier J.

Trends Biochem Sci. 2009 Nov;34(11):579-88. doi: 10.1016/j.tibs.2009.06.009. Epub 2009 Sep 26. Review.

Items per page

Supplemental Content

Write to the Help Desk